Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Daratumumab、Bortezomib 和 Dexamethasone 治疗既往接受过治疗的多发性骨髓瘤患者的总生存期 (CASTOR)：一项随机、开放标签的 III 期试验
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.21.02734
Sonneveld, Pieter; Chanan-Khan, Asher; Weisel, Katja; Nooka, Ajay K; Masszi, Tamas; Beksac, Meral; Spicka, Ivan; Hungria, Vania; Munder, Markus; Mateos, Maria-Victoria; Mark, Tomer M; Levin, Mark-David; Ahmadi, Tahamtan; Qin, Xiang; Garvin Mayo, Wendy; Gai, Xue; Carey, Jodi; Carson, Robin; Spencer, Andrew
